Table 2 Intraocular pressure and number of IOP lowering medication after MicroShunt implantation during follow-up.

From: Five-year follow-up with the PreserFlo MicroShunt for open-angle glaucoma

Visit

IOP (in mmHg)

IOP-lowering medication

 

observed means (SD)

estimated mean differences (95%-CI)

observed means (SD)

estimated mean differences (95%-CI)

Baseline

21.8 (4.2)

–

2.5 (1.4)

–

Year 1

12.5 (4.7)

–9.3 (–7.7 to –10.8)*

0.7 (1.2)

–1.9 (–1.4 to –2.3)*

Year 2

12.8 (5.1)

–9.0 (–7.5 to –10.5)*

0.9 (1.3)

–1.7 (–1.2 to –2.1)*

Year 3

13.3 (4.0)

–8.5 (–7.0 to –10.0)*

0.8 (1.3)

–1.7 (–1.2 to –2.1)*

Year 4

13.1 (4.1)

–8.7 (–7.2 to –10.3)*

1.0 (1.2)

–1.5 (–1.1 to –1.9)*

Year 5

13.1 (5.0)

–8.5 (–7.0 to –10.1)*

1.0 (1.2)

–1.4 (–1.0 to –1.9)*

  1. Values are presented in observed means (standard deviation) and estimated mean differences (95% confidence interval). Estimated mean differences are based on estimated marginal means in comparison to baseline. Data was censored after additional glaucoma intervention. *p < 0.001 compared with baseline values.
  2. CI confidence interval, IOP intraocular pressure, SD standard deviation.
Back to article page